These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 26248024)

  • 21. 111In-cetuximab-F(ab')2 SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts.
    van Dijk LK; Hoeben BA; Stegeman H; Kaanders JH; Franssen GM; Boerman OC; Bussink J
    Radiother Oncol; 2013 Sep; 108(3):484-8. PubMed ID: 23932156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.
    van Dijk LK; Yim CB; Franssen GM; Kaanders JH; Rajander J; Solin O; Grönroos TJ; Boerman OC; Bussink J
    Contrast Media Mol Imaging; 2016; 11(1):65-70. PubMed ID: 26242487
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
    Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
    J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor imaging in human head and neck cancer xenografts.
    van Dijk LK; Boerman OC; Kaanders JH; Bussink J
    Acta Oncol; 2015; 54(9):1263-7. PubMed ID: 26248024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging.
    van Dijk LK; Boerman OC; Kaanders JH; Bussink J
    Clin Cancer Res; 2015 Aug; 21(16):3602-9. PubMed ID: 25931452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
    Juergens RA; Bratman SV; Tsao MS; Laurie SA; Sara Kuruvilla M; Razak AR; Hansen AR
    Cancer Treat Rev; 2017 Mar; 54():43-57. PubMed ID: 28192747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming radioresistance in head and neck squamous cell carcinoma.
    Yamamoto VN; Thylur DS; Bauschard M; Schmale I; Sinha UK
    Oral Oncol; 2016 Dec; 63():44-51. PubMed ID: 27938999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma.
    Bossi P; Resteghini C; Paielli N; Licitra L; Pilotti S; Perrone F
    Oncotarget; 2016 Nov; 7(45):74362-74379. PubMed ID: 27556186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches.
    Spiegelberg D; Nilvebrant J
    Contrast Media Mol Imaging; 2017; 2017():2709547. PubMed ID: 29097914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma.
    Li D; Li X; Zhao J; Tan F
    J Transl Med; 2022 Aug; 20(1):358. PubMed ID: 35962347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings.
    Milas L; Mason KA; Ang KK
    Int J Radiat Biol; 2003 Jul; 79(7):539-45. PubMed ID: 14530163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer.
    Pantaleo MA; Nannini M; Maleddu A; Fanti S; Nanni C; Boschi S; Lodi F; Nicoletti G; Landuzzi L; Lollini PL; Biasco G
    Ann Oncol; 2009 Feb; 20(2):213-26. PubMed ID: 18842614
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.